Bristol, Pfizer, Novartis Forecasts Face FX Pressures

By | January 27, 2015

Scalper1 News

Three big pharmas reported strong fourth quarters but gave soft guidance Tuesday, as foreign-exchange rates continued to drag on expectations. Bristol-Myers Squibb (BMY) said its Q4 profit excluding one-time items was 46 cents a share, down 10% from the year-earlier quarter but 5 cents above analysts’ consensus, according to Thomson Reuters. Sales shrank 4% to $4.26 billion, beating consensus by about $200 million. For the year, earnings rose 2% Scalper1 News

Scalper1 News